Zolbetuximab in the treatment of advanced gastric and gastroesophageal junction cancer: a systematic review - Takeaways - MDSpire

Zolbetuximab in the treatment of advanced gastric and gastroesophageal junction cancer: a systematic review

  • By

  • Natalia Picheta

  • Julia Piekarz

  • Jakub Pobideł

  • Katarzyna Szklener

  • Magdalena Skórzewska

  • July 16, 2026

Share

  • 1

    Zolbetuximab is a chimeric monoclonal antibody targeting CLDN18.2, overexpressed in 50–80% of gastric cancers.

  • 2

    Phase II studies showed zolbetuximab improved progression-free survival and overall survival when added to chemotherapy.

  • 3

    The SPOTLIGHT study indicated that zolbetuximab reduced the risk of death by 25% when combined with mFOLFOX6.

  • 4

    The GLOW study demonstrated a nearly 23% reduction in death risk with zolbetuximab added to CAPOX.

  • 5

    Common adverse events associated with zolbetuximab include nausea and vomiting, primarily during the first treatment cycle.

Original Source(s)

Zolbetuximab in the treatment of advanced gastric and gastroesophageal junction cancer: a systematic review

  • by Natalia Picheta, Julia Piekarz, Jakub Pobideł, Katarzyna Szklener, Magdalena Skórzewska

  • July 16, 2026

Related Content

Responsible artificial intelligence in medical imaging: a systematic review

Treatment patterns and outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia: a single center study from Oman

Metabolomics-assisted evaluation of differences and clinical value between ablation and surgical treatment for lung adenocarcinoma